Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Postma EL, Verkooijen HM, van Esser S et al (2012) Efficacy of radioguided occult lesion localisation (ROLL) versus wire guided localisation (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised control trial. Breast Cancer Res Treat 136:469–478PubMedCrossRef
2.
Ocal K, Gunay E, Yucel E, Duce M (2011) Radioguided occult lesion localization versus wire-guided localization for non-palpable breast lesions: randomized controlled trial. Clinics 66(6):1003–1100PubMedCrossRef
3.
Medina-Franco H, Abarca-Perez L, Garcıa-Alvarez MN et al (2008) Radioguided occult lesion localization (ROLL) versus wire- guided lumpectomy for non-palpable breast lesions: a randomized prospective evaluation. J Surg Oncol 97:108–111PubMedCrossRef
4.
Moreno M, Wiltgen JE, Bodanese B et al (2008) Radioguided breast surgery for occult lesion localization—correlation between two methods. J Exp Clin Cancer Res 27:29PubMedCrossRef
5.
Rampaul RS, Bagnall M, Burrell H, Pinder SE, Evans AJ, Macmillan RD (2004) Randomized clinical trial comparing radioisotope occult lesion localization and wire-guided excision for biopsy of occult breast lesions. Br J Surg 91:1575–1577PubMedCrossRef
6.
Martinez AM, Sola M, de Tudela AP et al (2009) Radioguided localization of nonpalpable breast cancer lesions: randomized comparison with wire localization in patients undergoing conservative surgery and sentinel node biopsy. AJR Am J Roentgenol 193:1001–1009CrossRef
7.
Sajid M, Parampalli U, Haider Z, Bonomoi R (2012) Comparison of radioguided occult lesion localization (ROLL) and wire localization for non-palpable breast cancers: a meta-analysis. J Surg Oncol 105:852–858PubMedCrossRef
8.
Ahmed M (2012) The significance of the volume of excised specimens in radioguided occult lesion localization (ROLL). J Surg Oncol. doi:10.​1002/​jso.​23311 (epub ahead of print)
1.
2.
van der Ploeg IM, Hobbelink M, van den Bosch MA, Mali WP, Rinkes IHB, van Hillegersberg R (2008) 'Radioguided occult lesion localisation’ (ROLL) for non-palpable breast lesions: areview of the relevant literature. Eur J Surg Oncol 34(1):1–5. doi:10.​1016/​j.​ejso.​2007.​03.​002 PubMedCrossRef
Metadata
Title
Time to ROLL with it?
Author
Muneer Ahmed
Publication date
01-04-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2515-0

Other articles of this Issue 3/2013

Breast Cancer Research and Treatment 3/2013 Go to the issue

Clinical trial

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

Preclinical study

Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast

Preclinical study

Effect of selumetinib on the growth of anastrozole-resistant tumors

Review

Trends in breast cancer incidence and mortality in the United States: implications for prevention

Preclinical study

Genomic and expression analysis of microdissected inflammatory breast cancer

Clinical Trial

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits